Pharmacoeconomic scenario ofhypolipidemic drugs in the indian market

Hyperlipidemia can be inherited and increases the risk of disease of the blood vessels leading cardiovascular events and requiring lifelong therapy. Hence the cost of medication plays an important in patient care arising the need for all physicians to keep oneself updated regarding latest prices and price variation of various brands of hypolipidemic drugs. Objective: To analyze the cost variation of hypolipidemic drugs in Indian market. Materials and Methods: The Prices of different Hypolipidemic drugs manufactured by different Pharmaceutical companies were taken form IRD tripeli (Indian Drug Review) drug compendium 2017. The difference in the minimum and maximum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per 10 tablets was calculated. Results: A total of 21 drugs (11 single 10 combination preparation) which were manufactured by different companies were analyzed .In single drug therapy atorvastatin 20 mg has maximum percentage (1017.78%) variation while pravastatin 10 mg has minimum percentage variation (1.01%). Among lipoprotein lipase activators Finofibrate 200mg showed maximum variation (549.43%) and Bezafibrate 200 mg has least percentage variation (10%). Conclusion: In the Indian market, there is a wide cost variation among different brands of oral hypolipidemic drugs of same strength and dosage forms. Therefore, physicians should be encouraged to prescribe the drugs by generic names as they are cheaper and in no way inferior to costlier branded counterpart. This would alsoreduce the economic burden on the patients.